SALT LAKE CITY, June 24, 2024 (GLOBE NEWSWIRE) -- A significant 40% of Americans report feeling ‘depressed and/or anxious’ around the election season according to the latest GeneSight® Mental Health Monitor: Special Election Series, a nationwide survey from Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine. “The results of the Special Election Survey show that politics and elections tend to trouble our nation’s mental wellbeing,” said Thomas J. Valente, a psychiatrist f ...

Myriad Genetics, Inc. (MYGN) recently announced a collaboration with GSK plc (GSK) to advance in the field of genetic testing. The latest development is intended to improve access to homologous recombination deficiency (HRD) diagnostic testing for high-grade ovarian cancer (HGSOC) patients.With this alliance, Myriad's MyChoice HRD Plus and MyChoice CDx Plus Tests, collectively known as Myriad's MyChoice Tests, are now part of a new sponsored testing program that is accessible in Argentina, Brazil, Chile, Co ...

Myriad Genetics’ (MYGN) strong product portfolio raises our optimism. The company’s impressive growth strategy also encourages us. However, macroeconomic issues impede growth. The stock carries a Zacks Rank #3 (Hold) currently.Myriad Genetics has so far made significant progress with its three strategic imperatives. First, the company is developing best-in-class quality products, services and accessibility to accelerate growth and reach more patients across diverse backgrounds. Second, the company is buildi ...

SALT LAKE CITY, June 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with GSK aimed at improving access to homologous recombination deficiency (HRD) diagnostic testing for high-grade serous ovarian cancer (HGSOC) patients. A new sponsored testing program leveraging Myriad's MyChoice HRD Plus and MyChoice CDx Plus Tests (collectively referred to as Myriad's MyChoice Tests) is now available in Argentina, Braz ...

SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced that Genetics in Medicine, an official journal of the American College of Medical Genetics and Genomics (ACMG), published a new study validating RiskScore®, Myriad's breast cancer risk assessment tool integrated into its MyRisk® Hereditary Cancer Test. RiskScore combines a polygenic risk score (PRS) validated for all ancestries with the Tyrer-Cuzick mode ...

Core Insights - Myriad Genetics announced the validation of its RiskScore tool for breast cancer risk assessment, published in Genetics in Medicine, which combines a polygenic risk score with the Tyrer-Cuzick model [1][2] Study Overview - The study analyzed outcomes from over 130,000 women who underwent Myriad's MyRisk Hereditary Cancer Test with RiskScore, showing that RiskScore significantly improved predictive accuracy for breast cancer risk compared to the Tyrer-Cuzick model alone, with an approximate two-fold increase in accuracy [2][3] - The study included women tested between 2017-2019 who did not have known pathogenic variants associated with breast cancer and had no prior breast cancer diagnosis [5] Clinical Implications - RiskScore reclassified approximately 1 in 5 women compared to the Tyrer-Cuzick model, potentially leading to better identification of women who may benefit from enhanced surveillance measures [3][4] - The integration of a polygenic risk score for all ancestries into Myriad's precision medicine tool allows for a more comprehensive risk assessment, particularly for women without pathogenic germline mutations [4][5] Company Background - Myriad Genetics is a leader in genetic testing and precision medicine, focusing on advancing health through genetic insights that improve patient care and reduce healthcare costs [6]

SALT LAKE CITY, May 23, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, and its collaborators will share data from seven studies at the 2024 ASCO Annual Meeting. Three studies led by Myriad focus on breast cancer risk assessment, and four additional studies will be shared by collaborators that will cover the company's Precise™ MRD Test, MyChoice® CDx HRD Companion Diagnostic Test, and the Myriad Collaborative Research Registry™ (MCRR). At bo ...

SALT LAKE CITY, May 23, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and its collaborators will share data from seven studies at the 2024 ASCO Annual Meeting. Three studies led by Myriad focus on breast cancer risk assessment, and four additional studies will be shared by collaborators that will cover the company’s Precise™ MRD Test, MyChoice® CDx HRD Companion Diagnostic Test, and the Myriad Collaborative Research Registry™ (MCRR). At b ...

Myriad Genetics, Inc. (MYGN) reported a loss of 1 cent per share in the first quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 11 cents. The figure improved from the year-ago quarter’s loss of 21 cents.The quarter’s adjustments exclude amortization expenses from acquired intangible assets, equity compensations and real estate optimization.RevenuesTotal revenues rose 12% year over year to $202.2 million in the quarter under review. The figure topped the Zacks Consensus Estimate by 4.6 ...